FINWIRES · TerminalLIVE
FINWIRES

Argenx's Vyvgart Hytrulo Likely to Get FDA Approval for Myositis, RBC Says

By

Argenx's (ARGX) Vyvgart Hytrulo is likely to get approval from the US Food and Drug Administration for adults with immune-mediated necrotizing myopathy and dermatomyositis, RBC Capital Markets analysts said in a note emailed Tuesday.

Analysts said that even if the FDA decides to play "hard ball" for dermatomyositis approval, a new larger trial is expected to be relatively straightforward.

RBC said that for immune-mediated necrotizing myopathy, commercial uptake could be very rapid, given that Vyvgart is the first drug to show benefits in phase 3 and neurologists are already familiar with it.

On dermatomyositis, analysts said that while the trial did not reach statistical significance, the Total Improvement Score benefit was consistent with immune-mediated necrotizing myopathy and phase 3 data outperformed phase 2.

RBC retained an outperform rating on the stock and increased its price target to $1,100 from $1,025.

Price: $995.61, Change: $+7.77, Percent Change: +0.79%

Related Articles

Wire

Update: Challenger Fiscal 2026 Normalized Earnings, Revenue Rise; Shares Gain 8%

(Updates with the stock movement in the headline and last paragraph.)Challenger (ASX:CGF) logged AU$0.645 in normalized EPS for fiscal 2026, compared with AU$0.616 a year ago, a Tuesday filing showed.Analysts polled by FactSet expected $0.65.For the 12 months ended June 30, revenue from ordinary activities was AU$2.94 billion versus AU$2.9 billion previously, the Australia-listed investment management company added.The board declared a final dividend of AU$0.16 per share, up from AU$0.15 a year earlier, and a special dividend of AU$0.015 per share. Both are payable Sept. 17 to shareholders on record as of Aug. 26.For fiscal 2027, the company expects core basic EPS of AU$0.45 to AU$0.49.The company also boosted its share buyback program by AU$300 million, taking the on-market authorization to AU$450 million.Challenger shares rose 8% in recent Tuesday trade.

ASX:CGF
Wire

Update: HUB24 Fiscal 2026 Earnings, Revenue Rise; Shares Down 8%

(Updates with the stock movement in the headline and last paragraph)HUB24 (ASX:HUB) logged AU$1.667 in underlying EPS for fiscal 2026, compared with AU$1.178 a year ago, a Tuesday filing showed.For the 12 months ended June 30, revenue from ordinary activities was AU$501.1 million versus AU$406.6 previously, the Australia-listed financial services company added.The board declared a final dividend of AU$0.42 per share, up from AU$0.32 a year earlier, payable Oct. 13 to shareholders on record as of Sept. 8.The company's shares fell nearly 8% in recent Tuesday trade.

ASX:HUB
Wire

Update: Reliance Worldwide Enters Process Deed With Brookfield Over AU$4.1 Billion Takeover Proposal; Shares Jump 24%

(Updates to add stock movement in the headline and the fifth paragraph.)Reliance Worldwide (ASX:RWC) entered into a process deed with Brookfield Capital Partners following Brookfield's unsolicited, non-binding, indicative proposal to acquire Reliance Worldwide shares by way of a scheme of arrangement at AU$4.75 per share, according to a Tuesday Australian bourse filing.The company said the proposal reflects an enterprise value of about AU$4.1 billion and a transaction multiple of 12.1 times fiscal 2026 earnings before interest, taxes, depreciation and amortization (EBITDA) on a post-AASB16 basis, with the board determining to enter into the process deed to enable Brookfield to advance the proposal.Under the process deed, Reliance Worldwide has agreed to exclusivity restrictions including non-solicit, no talk and no due diligence obligations from Aug. 17 to Sept. 15, the filing added.Brookfield has agreed that any scheme implementation deed will include a 30-day "go-shop" provision, under which Reliance Worldwide will be allowed to solicit third-party interest, provide due diligence information and negotiate terms of any alternative proposal, it added.Its shares jumped 24% in recent trading on Tuesday.

ASX:RWC